Oats, rye bran may reduce weight gain, hepatic inflammation | WeForNews | Latest News, Blogs Oats, rye bran may reduce weight gain, hepatic inflammation – WeForNews | Latest News, Blogs
Connect with us

Health

Oats, rye bran may reduce weight gain, hepatic inflammation

The findings suggest that both brans have the capacity to create a favourable environment in the gut by supporting the growth of beneficial microbes.

Published

on

Oats Idli

London, July 5 : Want to lose some weight? Read on. Researchers have found that the consumption of dietary fibre from oat and rye brans increased the growth of beneficial microbes in the intestines and reduced hepatic inflammation.

In addition, diets enriched with oat or rye bran were shown to attenuate weight gain. The effects of oat and rye were partly different, but both were beneficial for health.

For the study, published in the Molecular Nutrition & Food Research, the research team from the University of Eastern Finland, VTT Technical Research Centre of Finland collaborated with the University of Hong Kong.

The health benefits of oat, rye and other whole-grain products have been widely studied, and their use has been associated with decreased inflammation and improved glucose, lipid and adipose tissue metabolism in human and animal experimental research.

In addition, they have been linked to a decreased risk of obesity, metabolic syndrome, cardiovascular diseases and type-2 diabetes. Different dietary fibres are also known to have different health effects.

In the current study, the research team wanted to investigate differences in metabolites produced by gut microbiota and their interactions with host metabolism in response to supplementation with oat and rye bran fibres.

The study was an animal experiment during which mice were fed a high-fat Western diet for 17 weeks. Two groups were fed the same diet enriched with 10 per cent of either oat or rye bran.

Among the various gut microbial metabolites, this study focused on those especially relevant to the development of fatty liver disease, which is often associated with obesity. Thus, microbial metabolites were assessed by measuring cecal short-chain fatty acids (SCFAs), ileal and faecal bile acids, and the expression of genes related to tryptophan metabolism.

The findings suggest that both brans have the capacity to create a favourable environment in the gut by supporting the growth of beneficial microbes.

Both bran fibres enhanced the production of SCFAs, leading to improved gut integrity, reduced liver inflammation. “In addition, both oat and rye supplementation were shown to attenuate weight gain associated with a high-fat diet,” the authors noted.

Health

PGI-Chandigarh among 17 trial sites for Oxford vaccine Covishield

The permission was granted after the Serum institute satisfied certain requirements sought by the Drug Controller in the design of the proposal.

Published

on

By

Covid 19 Vaccine

Chandigarh, Aug 4 : The PGI Hospital here is among the 17 trial sites in India for conducting the second and third phases of human clinical trials of Covishield, the potential vaccine developed by Oxford University, its director said on Tuesday.

The trials would involve administration of the vaccine to 1,600 healthy adults across 17 sites.

Postgraduate Institute of Medical Education and Research (PGIMER) Director Jagat Ram said, “It’s an honour to be entrusted with this vital responsibility of being one of the sites for phase two and three trials on Covishield vaccine.

“The results of phase one trials in the UK have been encouraging and did not present any serious adverse side effects. Phase two and three trials will be done on a larger human population to see its efficacy and requisite protection against COVID-19 in humans.”

Further detailing, the Director added, “As the results of the trials will have far reaching impact, we will strengthen our capacities, wherever required, to come out with tangible outcomes.

“A core group will be constituted to work out the modalities and comprehensive plan along with timelines to meet the desired expectations of Drugs Controller General of India and contribute towards containing the pandemic to the best of our abilities.”

Earlier, a committee of experts on COVID-19 under Central Drugs Standard Control Organisation (CDSCO) had recommended the Drugs Controller General of India (DCGI) to grant approval to the Serum Institute of India (SII) for conducting the Phase two and three trials.

The permission was granted after the Serum institute satisfied certain requirements sought by the Drug Controller in the design of the proposal.

In addition to PGIMER Chandigarh, the other sites for trials include AIIMS in Delhi, ABJ Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, AIIMS in Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysuru.

Continue Reading

Disaster

COVID-19 pandemic “once in a century”, but still “in our hands”: WHO

“I’m not saying there is no solution now. Whatever happens in the next few months or years, I also believe that it’s in our hands,” he said.

Published

on

By

Tedros Adhanom Ghebreyesus WHO

Geneva, Aug 4 : The chief of the World Health Organization (WHO) said that the COVID-19 pandemic is “a once-in-a-century health crisis,” but it is still “in our hands.”

WHO Director-General Tedros Adhanom Ghebreyesus said at a virtual press conference on Monday that the world has never seen anything like this pandemic for decades, and its effects might last for decades more, Xinhua news agency reported.

“Since we started probably recording, this is the first ever coronavirus-caused pandemic which has two dangerous combinations: it moves fast, and at the same time it’s a killer,” the WHO chief explained.

However, he noted, although the crisis is very severe, there are still solutions and hopes.

“I’m not saying there is no solution now. Whatever happens in the next few months or years, I also believe that it’s in our hands,” he said.

“Since the outbreak started, many countries have shown that it can be controlled, or serious transmission can be suppressed,” Tedros said, adding that he has mentioned many such countries in the past, including Spain, Italy, China and South Korea.

Continue Reading

Cities

Delhi govt bans use of hookah in hotels, restaurants to stem COVID-19 spread

Delhi has so far recorded 1,38,482 COVID-19 cases and 4,021 people have died due to the disease.

Published

on

hookah bar

New Delhi, Aug 3 : The Delhi government on Monday banned the use of hookahs, with or without tobacco, in all public places, including hotels, restaurants and bars, with immediate effect to control the spread of COVID-19.

Smokers are likely to be more vulnerable to COVID-19 as smoking means the fingers are in contact with the lips which increases the possibility of transmission of the virus, the health department said in an order.

“Smokers may also already have lung diseases or reduced lung capacity which would greatly increase the risk of serious illness,” it said.

Smoking products such as water pipes often involve the sharing of mouthpieces and hoses, which could facilitate the transmission of COVID-19 in communal and social settings, the health department said.

Therefore, the use and sharing of hookah, with or without tobacco (herbal hookah), “which might further increase the spread of SARS-CoV2, is strictly prohibited in all public places, including hotels, restaurants, bars, pubs, eateries, discotheques, etc. in Delhi with immediate effect to prevent and control the outbreak of COVID-19”, it said.

Delhi has so far recorded 1,38,482 COVID-19 cases and 4,021 people have died due to the disease.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.